Dr. Hisataka Kobayashi, is the Chief Scientist/ Senior investigator of the Molecular Imaging Program, National Cancer Institute/ NIH in Bethesda, Maryland, USA with over 30 years’ experience in research and development of cancer cell-specific imaging diagnosis, drug delivery, and therapy especially based on integrated science/technology of physics, chemistry, and medicine. Dr. Kobayashi established a newly developed, super cancer cell-selective therapy, near infrared photo-immunotherapy (NIR-PIT), using molecular targeting monoclonal antibodies conjugated with a photo-absorbing chemical (IR700) and near infrared light. NIR-PIT was licensed by Aspyrian Therapeutics in 2012. The first-in-human Phase 1 trial of NIR-PIT against head and neck cancer patients, who failed to be treated with all conventional cancer therapies, started in May 2015, and Phase 2 trial has completed in 2017 and is now in transition to designated fast-track Phase 3 in 2018. Dr. Kobayashi holds an MD in Radiology, and a PhD in Immunology/Internal Medicine both from Kyoto University, Kyoto, Japan, and has written or contributed to over 280 articles and 50 invited reviews and book chapters in English, 80 articles in Japanese, and gave over 300 invited lectures and talks in the basic and clinical bio-imaging/therapy fields especially in cancer.